Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020
Dexamethasone improves antiemetic control in lung cancer patients treated with chemotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 434s Year: 2007
Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Source: Eur Respir J 2006; 27: 1183-1189 Year: 2006
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013
Bevacizumab shows survival benefit for non-small lung cancer patients who received subsequent pemetrexed treatment but not had a therapeutic effect in clinical practice Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Metformin improves survival in lung cancer patients receiving EGFR-TKIs therapy> Source: International Congress 2018 – Lung cancer: from the bench to the bedside Year: 2018
The effectiveness of pegfilgrastim in preventing leucopenia in patients with lung cancer under chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 77s Year: 2005
Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Evaluation of outpatient infections in lung cancer patients treated with chemotherapy and/or radiotherapy Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012
Survival and respiratory effects in NSCLC patients after treatment with inhaled carboplatin Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy Source: Eur Respir J 2016; 48: 861-872 Year: 2016
Assessment of lung cancer related symptoms and chemotherapy related side effects in a group of patients with advanced lung cancer receiving palliative chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006
Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 301s Year: 2004
Predictive role of MMP-2 genetic variants on severe hematologic toxicity of NSCLC patients treated with first-line, platinum-based chemotherapy Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011
A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy Source: International Congress 2016 – Therapeutic trials in lung cancer Year: 2016
Combination chemotherapy with gemcitabine using isolated lung perfusion for the treatment of lung metastases Source: Eur Respir J 2004; 24: Suppl. 48, 42s Year: 2004
A phase II study of docetaxel in combination with carboplatin in the treatment of non-small cell lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer (NSCLC). A phase II study Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006
Outcome after pneumonectomy in non small cell lung cancer patients receiving a neoadjuvant therapy Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004
The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease. Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies Year: 2017